Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Executive Summary
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said
You may also be interested in...
OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent
OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent
OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan
OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa